The significance of intraperitoneal paclitaxel chemotherapy in the era of immunotherapy (KINGCA Week 2026) - Oct 11, 2026 - Abstract #AS1-1; Pres time: Sep 17, 2026; 09:00 AM - 09:20 AM; Location: Room B; "In ATTRACTION-4, progression- free survival favored nivolumab only in patients without peritoneal disease (HR 0.51 vs 1.04; interaction p=0.0013)...Catumaxomab met its primary endpoint in a randomized trial of 258 patients with malignant ascites and prolonged survival in the gastric subgroup (71 vs 44 days, p=0.0313); it was withdrawn from the European market in 2017 for commercial rather than clinical reasons, and approved again in 2025...Over the same period, cytoreductive surgery with HIPEC failed in PERISCOPE II. The 2026 IGCA consensus reflects this asymmetry."
Gastric Cancer • Microsatellite Instability • Solid Tumor • HER-2 • MSI • SPP1
|